Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
暂无分享,去创建一个
K. Rezvani | G. Garcia-Manero | Xuelin Huang | K. Patel | T. Kadia | F. Ravandi | E. Jabbour | N. Daver | R. Kanagal-Shamanna | J. Khoury | N. Jain | N. Short | P. Banerjee | Y. Alvarado | G. Montalban-Bravo | H. Kantarjian | Kun-Hee Kim | R. Garris | G. Issa | K. Chien | M. Kwari | M. Konopleva | Xianli Jiang | F. Haddad | W. Macaron | R. Delumpa | J. Thankachan | Xianli Jiang | Xianli Jiang | Xianli Jiang | Rebecca E. Garris
[1] E. Jabbour,et al. Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. , 2022, JAMA oncology.
[2] R. Foà,et al. P353: FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL , 2022, HemaSphere.
[3] M. Konopleva,et al. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse , 2022, Blood advances.
[4] S. Kasner,et al. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee , 2022, Journal of Hematology & Oncology.
[5] R. Foà,et al. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia , 2021, Blood advances.
[6] G. Rosti,et al. Ponatinib Dose-Ranging Study in Chronic-Phase Chronic Myeloid Leukemia: A Randomized, Open-Label Phase 2 Clinical Trial. , 2021, Blood.
[7] R. Foà,et al. Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab. , 2021, Blood.
[8] E. Jabbour,et al. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms , 2021, Leukemia.
[9] R. Foà,et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. , 2020, The New England journal of medicine.
[10] B. Druker,et al. Concomitant use of a dual ABL/Src kinase inhibitor eliminates the in vitroefficacy of blinatumomab against Ph+ ALL. , 2020, Blood.
[11] M. Konopleva,et al. Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors , 2019, American journal of hematology.
[12] M. Konopleva,et al. Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia , 2019, Blood.
[13] M. Konopleva,et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. , 2018, The Lancet. Haematology.
[14] M. Trková,et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. , 2017, Blood.
[15] P. Chevallier,et al. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] J. Radich,et al. US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.
[17] M. Konopleva,et al. Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis , 2016, Cancer.
[18] J. Cayuela,et al. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. , 2016, Blood.
[19] G. Garcia-Manero,et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.
[20] Z. Estrov,et al. Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.
[21] M. Konopleva,et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2015, Haematologica.
[22] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[23] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.